Our mision is focused on development of Exosomes and Extracellular Vesicles as new platforms for vaccines and diagnostic tools. The company was founded in March 2014 by researchers from the field of vesicles and exosomes and have industry experts in advisory roles.
ITSL’s objective is to improve the overall human and animal health by developing and commercializing the exosome technology platform for vaccines and diagnostic tools.
Passion for knowledge.
Leading group in Exosome Sciences.
Development of our approach.
Believing in our product.
Commitment for better and affordable therapies & diagnostics.
Our Business Model
Out licensing of the products after proof of concept with the possibility of the licensing of the technology platform itself.